BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
10/27/2022 3:05:58 AM | Browse: 198 | Download: 654
 |
Received |
|
2022-07-04 03:23 |
|
Peer-Review Started |
|
2022-07-04 03:25 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2022-08-13 22:08 |
|
Revised |
|
2022-08-26 21:05 |
|
Second Decision |
|
2022-09-26 03:46 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Company Editor-in-Chief |
|
2022-10-04 21:49 |
|
Articles in Press |
|
2022-10-04 21:49 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2022-10-10 07:10 |
|
Publish the Manuscript Online |
|
2022-10-27 03:05 |
| ISSN |
1948-5182 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Minireviews |
| Article Title |
Immunotherapy for hepatocellular carcinoma: A promising therapeutic option for advanced disease
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Gianluca Cassese, Ho-Seong Han, Boram Lee, Hae Won Lee, Jai Young Cho, Fabrizio Panaro and Roberto Ivan Troisi |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Ho-Seong Han, MD, PhD, Professor, Department of Surgery, Seoul National University Bundang Hospital, 300 Gumi-dong, Bundang-gu, Seongnam City, Gyeonggido, 463 707, Seongnam , South Korea. hanhs@snubh.org |
| Key Words |
Hepatocellular Carcinoma; Immunotherapy; Hepatocellular Carcinoma management; Hepatocellular Carcinoma therapy; Molecular targeted therapy |
| Core Tip |
Hepatocellular carcinoma (HCC) is associated with high rates of recurrence and mortality. Approximately 50% of the patients require systemic therapies, traditionally consisting of tyrosine kinase inhibitors, with poor outcomes. Recently, immune checkpoint inhibitors have revolutionized the management of HCC, providing new therapeutic options. Despite these major advances, the different factors involved in poor clinical responses and molecular pathways of escape following use of these therapies remain unclear. Other immune strategies, such as adoptive T-cell transfer, vaccination, virotherapy, and combinations of immunotherapy with other systemic or local treatments, are under evaluation. |
| Publish Date |
2022-10-27 03:05 |
| Citation |
Cassese G, Han HS, Lee B, Lee HW, Cho JY, Panaro F, Troisi RI. Immunotherapy for hepatocellular carcinoma: A promising therapeutic option for advanced disease. World J Hepatol 2022; 14(10): 1862-1874 |
| URL |
https://www.wjgnet.com/1948-5182/full/v14/i10/1862.htm |
| DOI |
https://dx.doi.org/10.4254/wjh.v14.i10.1862 |
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
